GlaxoSmithKline and ChemoCentryx Enter Into Drug Discovery and Development Alliance in Inflammatory Disorders London, UK, Philadelphia, PA and Mountain View, CA, USA; August 24, 2006 — GlaxoSmithKline (NYSE: GSK) and ChemoCentryx, Inc. today announced a worldwide multi-target strategic alliance to
ChemoCentryx Completes Series C Financing Mountain View, CA, USA; August 24, 2006 — ChemoCentryx, Inc. today announced that it has recently completed a Series C financing in June 2006 with participating investors including Jennison Associates, HBM BioVentures, Orbimed Advisors, Techne Corporation,
ChemoCentryx Names Regina E. Herzlinger to the Company's Board of Directors Mountain View, CA; February 7, 2006 — ChemoCentryx, Inc., a clinical-stage, biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine system,
ChemoCentryx Raises $33 Million in Private Financing June 17, 2004; San Carlos, Calif. — ChemoCentryx, Inc. today announced that it has closed a private financing round raising gross proceeds of $33 million. HBM BioVentures and Alta Partners acted as significant new investors in the round.